My wife, Jill, who is gene-positive with Huntington’s disease (HD), told me recently that she has to “pump herself up” to do almost anything now. It’s not just the big things, like medical ...

Arexera Therapeutics plans to launch a Phase 1 trial testing its experimental treatment ATL-101 in Huntington's patients ...

For Jill, the issue isn’t whether life has value. It is what kind of life is being preserved. If she can no longer eat without choking, recognize loved ones, or share what she wants, would inserting a ...

One thing that helps columnist Tanita Allen ease fear about future symptoms is separating what she can do today from what she ...

Differences in brain connections for people who carry a mutation known to cause Huntington’s disease are detectable decades before the onset of motor symptoms, a study showed. The findings suggested ...

Up to four years after a single dose of the experimental gene therapy ifezuntirgene inilparvovec (formerly AMT-130), people with Huntington’s disease who received the high dose showed slower disease ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google The first time I realized our kitchen had become a kind of care ...

Years ago, my wife, Jill, was at a party talking with a friend. The conversation turned personal, and her friend asked a difficult question. It was the kind of question people sometimes ask when they ...

In final 15-month study data, people with early-stage Huntington’s disease treated with SKY-0515, Skyhawk Therapeutics’ investigational oral therapy, showed improvements in function, movement, and ...

An early and progressive loss of a protein that helps maintain myelin, or the protective sheath around nerve fibers, may contribute to white matter damage in Huntington’s disease, a study suggests. In ...

uniQure has submitted an application to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of AMT-130, the Netherlands-based company’s gene therapy candidate for Huntington’s ...

A real-world study shows that the approved chorea treatment Austedo (deutetrabenazine) reduces involuntary movements in adults with Huntington’s disease and is generally well tolerated in clinical ...